# Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia

> **NCT02533232** · PHASE1 · UNKNOWN · sponsor: **Pakistan Institute of Living and Learning** · enrollment: 60 (estimated)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorder

## Interventions

- **DRUG:** Minocycline

## Key facts

- **NCT ID:** NCT02533232
- **Lead sponsor:** Pakistan Institute of Living and Learning
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-30
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533232, "Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02533232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*